Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.
about
Oncogenic role of leptin and Notch interleukin-1 leptin crosstalk outcome in cancerThe Interactions of Obesity, Inflammation and Insulin Resistance in Breast CancerWhy does obesity promote cancer? Epidemiology, biology, and open questionsObesity in cancer survivalLifestyle Factors in Cancer Survivorship: Where We Are and Where We Are HeadedBody mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studiesMinireview: Inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancersExemestane for breast cancer prevention: a critical shift?AGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011.Body mass index, diabetes, and triple-negative breast cancer prognosis.Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Endocrine therapy in obese patients with primary breast cancer: another piece of evidence in an unfinished puzzle.Novel drugs that target the estrogen-related receptor alpha: their therapeutic potential in breast cancerObesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland.p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors.Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer.Associations between self-reported post-diagnosis physical activity changes, body weight changes, and psychosocial well-being in breast cancer survivorsObesity-associated systemic interleukin-6 promotes pre-adipocyte aromatase expression via increased breast cancer cell prostaglandin E2 production.Race, response to chemotherapy, and outcome within clinical breast cancer subtypes.A Diet and Exercise Intervention during Chemotherapy for Breast Cancer.Increased serum tumor necrosis factor receptor-associated factor-6 expression in patients with non-metastatic triple-negative breast cancer.Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival.Weight gain increases human aromatase expression in mammary glandLifestyle factors associated with serum N-3 fatty acid levels in breast cancer patients.Targeting the COX-2 Pathway to Improve Therapeutic Response in the Obese Breast Cancer Patient PopulationPsychosocial intervention effects on adaptation, disease course and biobehavioral processes in cancer.Impact of body mass index on breast cancer in accordance with the life-stage of womenObesity Correlation With Metastases Development and Response to First-Line Metastatic Chemotherapy in Breast CancerCan we use gonadotropin plasma concentration as surrogate marker for BMI-related incomplete estrogen suppression in breast cancer patients receiving anastrozole?Prognostic impact of progesterone receptor status combined with body mass index in breast cancer patients treated with adjuvant aromatase inhibitor.Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial.Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index.Pre-diagnosis body mass index and survival after breast cancer in the After Breast Cancer Pooling Project.Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer.Variants in tamoxifen metabolizing genes: a case-control study of contralateral breast cancer risk in the WECARE study.Efficacy of tamoxifen ± aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial.Reduced-calorie dietary weight loss, exercise, and sex hormones in postmenopausal women: randomized controlled trial.Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.Aromatase inhibition 2013: clinical state of the art and questions that remain to be solvedBody mass index and survival after diagnosis of invasive breast cancer: a study based on the Japanese National Clinical Database-Breast Cancer Registry.
P2860
Q26750563-1C1FF9E0-1EC2-4ED1-9ADF-3E149184AADCQ26777775-01024B3C-7AB8-444A-8B72-299456D993A6Q26797301-35FB2E34-1F10-4822-A2EA-DF4C49D1F97EQ26863606-A03A6BB8-981E-4372-9436-04167F22EEF7Q27011454-85F22C0A-B7F5-4FFA-8433-269251DD173DQ27014939-44FE3CE1-E62F-4F60-8275-91D8A6A3E6CEQ27016106-1AF72E54-45BA-4D9F-9907-7E1E91E463AEQ27028211-0936070A-539E-4FD4-AC4C-A6FCB1DC0927Q30318240-9E57E971-2528-428F-BA9C-588A06C06F0AQ30458239-AC368807-F65D-4C33-A541-CF4F2AE479DAQ30543788-E0D4EC4E-857A-4C89-9FCC-FCB60F54829FQ33352521-5AB196AD-EF34-402B-858C-33D8184187B3Q33698278-AC22ED29-057F-4181-8326-3FF41B8AA45BQ34764480-0C4292DA-02A8-45D0-BF08-F40E0FC3FAD1Q35051755-C875EB2D-DF64-4582-B5F7-FB859FD4DC40Q35091234-B65C2077-B34E-4BA7-9D67-C78E5A6B0BC7Q35154605-60FC0719-6B3E-4512-A1D5-EA345BAE6D9DQ35535944-753FDCDF-0516-4B08-9C5A-234AE031EAF1Q35568229-6FFDDAE7-81FC-4117-B02E-71EA2B3E1EC3Q35660414-341F6D9A-695A-49B4-B489-BAADA4646E7FQ35759017-59BF090C-F875-4A84-A74D-F6BEE84A9CD8Q35834893-9616D064-235B-4F31-A97B-4B2F03DF9BB0Q35854642-1ECAF680-B11E-412B-AE87-DA8D66A066B0Q36012987-CBACA4CA-6385-4EC5-8942-44AA238C0B51Q36114823-8A1CDD70-7EA3-4444-A98D-170C4957C4B9Q36240714-FA1B5F57-AC3C-4CDA-97C8-D3A4E5E634BCQ36296120-84C2316A-D8CB-469A-84C1-01BAFA0FA0AEQ36318861-341148F4-37AE-4A15-A5F9-14A6FE150AD4Q36325915-6BB4DC86-786F-4EDF-BBFC-EDDFF7286859Q36334705-9B4B969C-63FF-4BE8-A8F6-2E02C268E412Q36368902-B8016BB5-305E-4969-86FC-91DD7A910014Q36419177-32A5F2BA-520D-4B8C-8717-17BCEE875D39Q36426540-C5DDE2C1-BCC6-4AB4-B187-C26784F35384Q36650415-91E243FE-F06F-4ACD-84D5-FA44646EE9FCQ36729040-1B210A39-46A8-4C2C-9EB9-A534BA640A08Q36775349-70E414EB-0CDF-4025-A602-719FCA224F7BQ36910418-3E78923E-9585-40D0-BA17-4770ACF36F69Q36915182-1BF1F509-3B02-4CF5-A8A8-CC707361CC74Q36946008-E45EB711-F311-457B-AF0C-189760B0343FQ37045620-0F72FE10-A712-4290-9E52-84F8B80A2DB7
P2860
Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Effect of body mass index on r ...... analysis from the ATAC trial.
@en
Effect of body mass index on r ...... analysis from the ATAC trial.
@nl
type
label
Effect of body mass index on r ...... analysis from the ATAC trial.
@en
Effect of body mass index on r ...... analysis from the ATAC trial.
@nl
prefLabel
Effect of body mass index on r ...... analysis from the ATAC trial.
@en
Effect of body mass index on r ...... analysis from the ATAC trial.
@nl
P2093
P50
P356
P1476
Effect of body mass index on r ...... analysis from the ATAC trial.
@en
P2093
Jack Cuzick
John F Forbes
Wolfgang Distler
P304
P356
10.1200/JCO.2009.27.2021
P407
P577
2010-06-14T00:00:00Z